Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine morning-timed therapy in type 2 diabetes mellitus
NL-OMON49251Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bromocriptine in type 2 diabetes mellitus (T2DM) and insulin resistance (IR), sponsored by Amsterdam University Medical Center. Primary endpoints: Dexamphetamine-stimulated dopamine release, Adipose tissue insulin sensitivity and 3 more. Started May 2019; status: active, not recruiting.
02
Drugs
bromocriptine
03
Conditions
type 2 diabetes mellitus (T2DM)insulin resistance (IR)
Beyond the preview
Go deeper on NL-OMON49251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49251.